SV2005001973A - Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500) - Google Patents
Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)Info
- Publication number
- SV2005001973A SV2005001973A SV2004001973A SV2004001973A SV2005001973A SV 2005001973 A SV2005001973 A SV 2005001973A SV 2004001973 A SV2004001973 A SV 2004001973A SV 2004001973 A SV2004001973 A SV 2004001973A SV 2005001973 A SV2005001973 A SV 2005001973A
- Authority
- SV
- El Salvador
- Prior art keywords
- useful
- treatment
- wyth0090
- kinolines
- cardiovascular diseases
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
PROVEE COMPUESTOS DE LA FORMULA I VER FORMULA CUALES SON UTILES EN EL TRATAMIENTO O INHIBICION DE LAS ENFERMEDADES MEDIADAS POR LXR
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52900903P | 2003-12-12 | 2003-12-12 | |
US60029604P | 2004-08-10 | 2004-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2005001973A true SV2005001973A (es) | 2005-11-04 |
Family
ID=34704262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2004001973A SV2005001973A (es) | 2003-12-12 | 2004-12-10 | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500) |
Country Status (18)
Country | Link |
---|---|
US (1) | US7576215B2 (es) |
EP (2) | EP2284157A1 (es) |
JP (1) | JP2007516258A (es) |
KR (1) | KR20070001922A (es) |
AR (1) | AR047329A1 (es) |
AU (1) | AU2004298486A1 (es) |
BR (1) | BRPI0417543A (es) |
CA (1) | CA2547518A1 (es) |
CR (1) | CR8410A (es) |
EC (1) | ECSP066635A (es) |
IL (1) | IL175892A0 (es) |
NO (1) | NO20062561L (es) |
PA (1) | PA8619901A1 (es) |
PE (1) | PE20050676A1 (es) |
RU (1) | RU2006124843A (es) |
SV (1) | SV2005001973A (es) |
TW (1) | TW200529845A (es) |
WO (1) | WO2005058834A2 (es) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1487776A4 (en) * | 2002-03-27 | 2005-05-25 | Smithkline Beecham Corp | ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF |
ATE453389T1 (de) * | 2002-03-27 | 2010-01-15 | Smithkline Beecham Corp | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen |
US7247748B2 (en) * | 2002-03-27 | 2007-07-24 | Smithkline Corporation | Amide compounds and methods of using the same |
EP1575495A4 (en) * | 2002-03-27 | 2009-12-02 | Smithkline Beecham Corp | COMPOUNDS AND METHODS |
JP4875978B2 (ja) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
EP1745800A4 (en) * | 2004-04-26 | 2009-11-18 | Ono Pharmaceutical Co | NEW BLT2-MEDIATED DISEASE AND BLT2 BINDING AND CONNECTION |
US20070299092A1 (en) * | 2004-05-20 | 2007-12-27 | Wyeth | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors |
WO2007002654A2 (en) | 2005-06-28 | 2007-01-04 | Daiichi Sankyo Company, Limited. | Lxr ligand testing method |
GB0521083D0 (en) * | 2005-10-17 | 2005-11-23 | Novartis Ag | Organic compounds |
US20070093524A1 (en) * | 2005-10-25 | 2007-04-26 | Wyeth | 5-Lipoxygenase modulators |
US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
WO2008036238A2 (en) * | 2006-09-19 | 2008-03-27 | Wyeth | Use of lxr modulators for the prevention and treatment of skin aging |
WO2008036239A2 (en) * | 2006-09-19 | 2008-03-27 | Wyeth | Use of lxr agonists for the treatment of osteoarthritis |
TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
EP2099444A4 (en) * | 2006-12-14 | 2012-11-07 | Nps Pharma Inc | USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES |
US20090069373A1 (en) * | 2007-02-28 | 2009-03-12 | Wyeth | Quinoline Acids |
ES2320955B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
EP2121591A2 (en) * | 2007-03-08 | 2009-11-25 | Plexxikon, Inc. | Ppar active compounds |
ES2329639B1 (es) * | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
AU2008264999B8 (en) * | 2007-06-18 | 2013-10-31 | Richter Gedeon Nyrt. | Sulfonyl-quinoline derivatives |
US8063220B2 (en) | 2007-06-22 | 2011-11-22 | Richter Gedeon Nyrt. | Sulfonyl-quinoline derivatives |
JP5269086B2 (ja) | 2007-11-15 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
JP5285709B2 (ja) | 2007-11-16 | 2013-09-11 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
WO2009086138A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth | Benzimidazole compounds |
WO2009102789A2 (en) * | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteroarthritis |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) * | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
WO2009133692A1 (ja) | 2008-04-30 | 2009-11-05 | 興和株式会社 | キノリン化合物 |
BRPI0913212A2 (pt) | 2008-05-29 | 2019-09-24 | Kowa Co | composto de carbinol, remédio, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doença, e, uso do derivado de carbinol ou sal do mesmo, ou seu solvato |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
PT2959900T (pt) * | 2008-06-16 | 2017-06-22 | Univ Tennessee Res Found | Composto para tratamento do cancro |
CN102137836B (zh) * | 2008-07-28 | 2015-08-26 | 赛丹思科大学 | 用于治疗代谢疾病的化合物 |
JP5281647B2 (ja) * | 2008-09-08 | 2013-09-04 | 日本曹達株式会社 | 含窒素ヘテロ環化合物およびその塩並びに農園芸用殺菌剤 |
EP2352725A1 (en) * | 2008-11-07 | 2011-08-10 | Wyeth LLC | Quinoxaline-based lxr modulators |
RU2404971C2 (ru) * | 2008-12-02 | 2010-11-27 | ЗАО "Фарм-Синтез" | Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе |
US8598354B2 (en) | 2008-12-05 | 2013-12-03 | University Of South Florida | Compounds having antiparasitic or anti-infectious activity |
WO2010065905A2 (en) * | 2008-12-05 | 2010-06-10 | Oregon Health & Science University | Compounds having antiparasitic or anti-infectious activity |
NZ595910A (en) | 2009-04-29 | 2013-06-28 | Kowa Co | Carbinol compound having heterocyclic linker |
AU2010243353B2 (en) | 2009-04-30 | 2014-09-11 | Astex Therapeutics Limited | Imidazole derivatives and their use as modulators of Cyclin dependent Kinases |
EP2445902A2 (en) * | 2009-06-25 | 2012-05-02 | Amgen, Inc | Heterocyclic compounds and their uses as inhibitors of pi3k activity |
MX2012010115A (es) | 2010-03-01 | 2013-02-26 | Gtx Inc | Compuestos para el tratamiento de cancer. |
JP2013531007A (ja) * | 2010-07-08 | 2013-08-01 | ワイス・エルエルシー | 皮膚障害の治療に有用な新規キノリンエステル |
CN103517908A (zh) | 2010-09-07 | 2014-01-15 | Seoul大学校产学协力财团 | 二倍半萜化合物及其用途 |
ES2379242B1 (es) * | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromeno. |
JP6320382B2 (ja) | 2012-08-13 | 2018-05-09 | ザ ロックフェラー ユニヴァーシティ | メラノーマの処置および診断 |
SG11201502935VA (en) | 2012-10-16 | 2015-09-29 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror-gamma-t |
CA2888480C (en) | 2012-10-16 | 2021-03-16 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of ror.gamma.t |
NZ706775A (en) | 2012-10-16 | 2018-10-26 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
CN103965105A (zh) * | 2013-01-29 | 2014-08-06 | 中山大学 | 苯乙烯基喹啉衍生物及其在治疗阿尔茨海默病症中的应用 |
JPWO2014123203A1 (ja) * | 2013-02-06 | 2017-02-02 | 京都薬品工業株式会社 | 糖尿病治療薬 |
CN109568312A (zh) | 2013-03-05 | 2019-04-05 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
KR20160068956A (ko) | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | RORyT의 퀴놀리닐 조절제 |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
EP3057421B1 (en) | 2013-10-15 | 2019-11-20 | Janssen Pharmaceutica NV | Alkyl linked quinolinyl modulators of ror(gamma)t |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
JP6320523B2 (ja) | 2013-10-15 | 2018-05-09 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγTの第二級アルコールキノリニルモジュレータ |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
CN104036909B (zh) * | 2014-06-25 | 2016-09-28 | 桂林理工大学 | 磁性材料[Cu3(N3)6(DMF)2]n及合成方法 |
WO2016057454A1 (en) | 2014-10-06 | 2016-04-14 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
CN109069461A (zh) | 2016-01-11 | 2018-12-21 | 洛克菲勒大学 | 与髓源性抑制细胞相关的病症的治疗方法 |
EP3246028A1 (en) * | 2016-05-18 | 2017-11-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline compounds for increasing insuline release |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
EP3621951A4 (en) * | 2017-05-12 | 2021-01-27 | Research Triangle Institute | DIARYL URINE AS CB1 ALLOSTERIC MODULATORS |
WO2019074241A1 (ko) * | 2017-10-11 | 2019-04-18 | 정원혁 | 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제 |
US11505559B2 (en) | 2017-10-30 | 2022-11-22 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors |
EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
EP3887401A2 (en) | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
KR20220087497A (ko) | 2019-10-18 | 2022-06-24 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 병원성 혈관을 표적화하기 위한 화합물 및 방법 |
WO2021096589A1 (en) * | 2019-11-15 | 2021-05-20 | Georgia State University Research Foundation, Inc. | Small molecules polymerase inhibitors |
CA3161274A1 (en) | 2019-12-13 | 2021-06-17 | Stephen Wald | Metal salts and uses thereof |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6350351B2 (es) | 1978-01-28 | 1988-10-07 | Sheru Intern Risaachi Maachatsupii Bv | |
US4407803A (en) | 1981-08-17 | 1983-10-04 | Abbott Laboratories | Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives |
DE3413078A1 (de) | 1984-04-06 | 1985-10-24 | Miles Laboratories, Inc., Elkhart, Ind. | Chromogene aminosaeure- und peptidester, verfahren zu deren herstellung, verwendung dieser verbindungen in analysenverfahren sowie mittel zum nachweis esterolytischer und/oder proteolytischer enzyme |
CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
US4761419A (en) | 1987-12-07 | 1988-08-02 | Warner-Lambert Company | 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
NZ231631A (en) | 1988-12-08 | 1992-07-28 | Duphar Int Res | Heterocyclically-substituted piperazine and diazepine derivatives and anxiolytic compositions |
DE3905908A1 (de) * | 1989-02-25 | 1990-09-06 | Bayer Ag | Substituierte chinoline, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
DE3908298A1 (de) | 1989-03-14 | 1990-09-20 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-n,n'-sulfonylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
DE3916663A1 (de) | 1989-05-23 | 1990-11-29 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
DE3927369A1 (de) | 1989-08-19 | 1991-02-21 | Bayer Ag | Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe |
DE3927931A1 (de) | 1989-08-24 | 1991-02-28 | Bayer Ag | Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate |
DE3927930A1 (de) | 1989-08-24 | 1991-02-28 | Bayer Ag | Cyclisch substituierte (chinolin-2-yl-methoxy)phenyl-essig-saeure-derivate |
MX22406A (es) | 1989-09-15 | 1994-01-31 | Pfizer | Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat). |
DE3935139A1 (de) | 1989-10-21 | 1991-04-25 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-thioharnstoffe |
DE3935491A1 (de) | 1989-10-25 | 1991-05-02 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-carbonylharnstoffe |
JPH03181465A (ja) * | 1989-12-11 | 1991-08-07 | Takeda Chem Ind Ltd | キノリン誘導体 |
GB9113137D0 (en) | 1990-07-13 | 1991-08-07 | Ici Plc | Thioxo heterocycles |
JPH04182469A (ja) | 1990-11-16 | 1992-06-30 | Terumo Corp | 新規なチオエステル化合物 |
JP2696150B2 (ja) | 1991-02-05 | 1998-01-14 | 株式会社大塚製薬工場 | キノリン誘導体 |
US6004979A (en) | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
DE4139751A1 (de) | 1991-12-03 | 1993-06-09 | Bayer Ag, 5090 Leverkusen, De | Thiazolyl substituierte chinolylmethoxyphenylessigsaeurederivate |
DE4105551A1 (de) | 1991-02-22 | 1992-08-27 | Bayer Ag | 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
DE4112533A1 (de) | 1991-04-17 | 1992-10-22 | Bayer Ag | Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren |
DE9290049U1 (de) * | 1991-04-26 | 1994-01-05 | Pfizer | 4-Aryl-3-(heteroarylureido)chinolin-Derivate |
US5366987A (en) * | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
DE4128681A1 (de) | 1991-08-29 | 1993-03-04 | Bayer Ag | Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
JP3130342B2 (ja) | 1991-10-04 | 2001-01-31 | 日産化学工業株式会社 | 動脈硬化性血管内膜肥厚抑制薬 |
JPH05128327A (ja) | 1991-11-01 | 1993-05-25 | Mitsubishi Electric Corp | Icカード |
JPH05130897A (ja) | 1991-11-11 | 1993-05-28 | Terumo Corp | チオール化合物測定用試薬組成物 |
DE4139749A1 (de) | 1991-12-03 | 1993-06-09 | Bayer Ag, 5090 Leverkusen, De | Chinolylmethoxyphenyl-essigsaeureamide |
DE4139750A1 (de) | 1991-12-03 | 1993-06-09 | Bayer Ag, 5090 Leverkusen, De | Chinolylmethoxyphenylessigsaeure-acylamide und -harnstoffe |
MX9300141A (es) * | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
US5183825A (en) | 1992-04-07 | 1993-02-02 | American Home Products Corporation | 4-arylmethyl-5-alkyl-3H-pyrazol-3-ones and hypoglycemic use |
EP0570112A1 (en) | 1992-04-23 | 1993-11-18 | Zeneca Limited | Cycloalkane derivatives |
DE4226519A1 (de) | 1992-08-11 | 1994-02-17 | Bayer Ag | 3-Substituierte Chinolylmethoxy-phenylessigsäurederivate |
JPH0692939A (ja) | 1992-09-16 | 1994-04-05 | Kyowa Hakko Kogyo Co Ltd | イミダゾール誘導体 |
DE4243279A1 (de) | 1992-12-21 | 1994-06-23 | Bayer Ag | Substituierte Triole |
DK0628550T3 (da) * | 1993-06-08 | 1998-09-28 | Vertex Pharma | Pyridazin som interleukin-1 beta-omdannede enzyminhibitorer |
JPH0710870A (ja) | 1993-06-23 | 1995-01-13 | Asahi Glass Co Ltd | 新規アミノピリジン誘導体およびその塩 |
US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
NZ274063A (en) * | 1993-09-17 | 1997-11-24 | Smithkline Beecham Corp | Cytokine suppressive anti-inflammatory drug binding protein (csbp) and its use |
JPH0789957A (ja) | 1993-09-22 | 1995-04-04 | Nissan Chem Ind Ltd | ビフェニルメチルアミン誘導体 |
US5453509A (en) | 1993-10-08 | 1995-09-26 | Synaptic Pharmaceutical Corporation | Functionalization of acyl pyridinium salts |
DE4411657A1 (de) | 1994-04-02 | 1995-10-05 | Basf Ag | Verfahren zur Herstellung von 6-Hydroxymethylchinolinen |
FR2722198B1 (fr) | 1994-07-08 | 1996-10-04 | Pf Medicament | 1derives de silylmethyl-anilines, le2fabrication, et leur utilisation co |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
SK1296A3 (en) | 1995-01-04 | 1996-08-07 | Bayer Ag | Acyled pseudopeptides with trifluoromethyl-substituted 2-azabicyklooctane, manufacturing process thereof and medicaments containing these substances |
DE19500122A1 (de) | 1995-01-04 | 1996-07-11 | Bayer Ag | Neue Pseudopeptide mit trifluormethyl-substituierten 2-Azabicyclooctan |
US5650415A (en) * | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
US5837719A (en) * | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
DE19532714A1 (de) | 1995-09-05 | 1997-03-06 | Bayer Ag | Kombination von 5-Lipoxygenase- und Leukotriensynthese Inhibitoren mit Glucocorticosteroiden |
JPH1067658A (ja) | 1995-09-13 | 1998-03-10 | Takeda Chem Ind Ltd | 免疫抑制剤 |
ID16283A (id) | 1996-03-20 | 1997-09-18 | Astra Pharma Prod | Senyawa yang berguna dibidang farmasi |
CZ296163B6 (cs) | 1996-05-20 | 2006-01-11 | Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV | |
EP0808627A2 (de) | 1996-05-22 | 1997-11-26 | Hoechst Aktiengesellschaft | Verwendung nicht-peptidischer Bradykinin-Antagonisten zur Behandlung und Prävention von chronisch-fibrogenetischen Lebererkrankungen, akuten Lebererkrankungen und den damit verbundenen Komplikationen |
JPH101471A (ja) | 1996-06-13 | 1998-01-06 | Green Cross Corp:The | N−[(キノリン−2−イル)フェニル]スルホンアミド類の結晶およびその製造方法 |
WO1998014430A1 (fr) | 1996-10-02 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Derives de pyrimidine |
DE69723863T2 (de) | 1996-11-06 | 2004-04-15 | Darwin Discovery Ltd., Slough | Chinoline und deren therapeutische verwendung |
WO1998034115A1 (en) | 1997-02-04 | 1998-08-06 | Trega Biosciences, Inc. | 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries |
DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
HUP0003364A3 (en) | 1997-06-19 | 2002-03-28 | Sepracor Inc Marlborough | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
AR016294A1 (es) | 1997-07-02 | 2001-07-04 | Smithkline Beecham Corp | Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion |
US6538022B1 (en) | 1997-09-24 | 2003-03-25 | Orion Corporation | Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors) |
JP2002508366A (ja) | 1997-12-12 | 2002-03-19 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的5−ht1a、5−ht1bおよび5−ht1d受容体アンタゴニストとしてのそれらの用途 |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
US6316503B1 (en) * | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
PT1106612E (pt) | 1999-11-30 | 2004-06-30 | Pfizer Prod Inc | Derivados de quinolina uteis para inibir a farnesil-proteina-transferase |
CA2392568A1 (en) | 1999-12-13 | 2001-06-14 | Merck & Co., Inc. | Method for the prevention and/or treatment of atherosclerosis |
GB0002032D0 (en) | 2000-01-28 | 2000-03-22 | Zeneca Ltd | Chemical compounds |
ES2262626T3 (es) | 2000-02-04 | 2006-12-01 | Janssen Pharmaceutica N.V. | Inhibidores de farnesil proteina transferasa para tratar cancer de mama. |
DE60130976T2 (de) | 2000-02-24 | 2008-07-17 | Janssen Pharmaceutica N.V. | Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs |
CA2397425A1 (en) | 2000-02-29 | 2001-09-07 | Ivan David Horak | Farnesyl protein transferase inhibitor combinations with taxane compounds |
US20030022918A1 (en) | 2000-02-29 | 2003-01-30 | Horak Ivan David | Farnesyl protein transferase inhibitor combinations with an her2 antibody |
AU2001252147A1 (en) | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations |
EP1261348A2 (en) | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
JP2003525237A (ja) | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 |
EP1261374A2 (en) | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
EP1261356A2 (en) | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
AU4742101A (en) | 2000-03-17 | 2001-10-03 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
AU4738101A (en) | 2000-03-17 | 2001-10-03 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
JP2001261654A (ja) | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
US6495562B1 (en) | 2000-04-25 | 2002-12-17 | Abbott Laboratories | Naphthamidine urokinase inhibitors |
AU2001262984A1 (en) * | 2000-05-03 | 2001-11-12 | Tularik, Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
WO2003024441A1 (fr) * | 2001-09-14 | 2003-03-27 | Shionogi & Co., Ltd. | Nouvelle utilisation de composes tricycliques |
WO2002012191A1 (fr) | 2000-08-08 | 2002-02-14 | Shionogi & Co., Ltd. | Derives d'amines cycliques et utilisation |
GB0023918D0 (en) | 2000-09-29 | 2000-11-15 | King S College London | Antiparasitic compounds |
AU1532802A (en) | 2000-10-12 | 2002-04-22 | Merck & Co Inc | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
US7226945B2 (en) | 2000-10-13 | 2007-06-05 | Astrazeneca Ab | Estrogen receptor-β ligands |
DE60223020T2 (de) | 2001-05-03 | 2008-07-24 | The University Of Chicago, Chicago | Leber x rezeptoragonisten |
JP2002371078A (ja) | 2001-06-12 | 2002-12-26 | Sankyo Co Ltd | キノリン誘導体及びキノロン誘導体 |
EP1270535A3 (de) | 2001-06-20 | 2004-02-18 | Clariant GmbH | Verfahren zur Herstellung von substituierten aromatischen Verbindungen |
FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
WO2003031408A2 (en) * | 2001-10-08 | 2003-04-17 | Eli Lilly And Company | Tricyclic compounds useful for modulating lxr |
WO2003082198A2 (en) * | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Methods of treatment with lxr modulators |
-
2004
- 2004-12-10 TW TW093138244A patent/TW200529845A/zh unknown
- 2004-12-10 AR ARP040104624A patent/AR047329A1/es not_active Application Discontinuation
- 2004-12-10 KR KR1020067014042A patent/KR20070001922A/ko not_active Application Discontinuation
- 2004-12-10 AU AU2004298486A patent/AU2004298486A1/en not_active Abandoned
- 2004-12-10 BR BRPI0417543-3A patent/BRPI0417543A/pt not_active IP Right Cessation
- 2004-12-10 SV SV2004001973A patent/SV2005001973A/es not_active Application Discontinuation
- 2004-12-10 US US11/010,236 patent/US7576215B2/en not_active Expired - Fee Related
- 2004-12-10 PA PA20048619901A patent/PA8619901A1/es unknown
- 2004-12-10 JP JP2006544016A patent/JP2007516258A/ja active Pending
- 2004-12-10 WO PCT/US2004/041399 patent/WO2005058834A2/en active Application Filing
- 2004-12-10 PE PE2004001236A patent/PE20050676A1/es not_active Application Discontinuation
- 2004-12-10 RU RU2006124843/04A patent/RU2006124843A/ru not_active Application Discontinuation
- 2004-12-10 EP EP10181673A patent/EP2284157A1/en not_active Withdrawn
- 2004-12-10 CA CA002547518A patent/CA2547518A1/en not_active Abandoned
- 2004-12-10 EP EP04813688A patent/EP1692111A2/en not_active Withdrawn
-
2006
- 2006-05-19 CR CR8410A patent/CR8410A/es not_active Application Discontinuation
- 2006-05-24 IL IL175892A patent/IL175892A0/en unknown
- 2006-06-02 NO NO20062561A patent/NO20062561L/no not_active Application Discontinuation
- 2006-06-12 EC EC2006006635A patent/ECSP066635A/es unknown
Also Published As
Publication number | Publication date |
---|---|
NO20062561L (no) | 2006-09-08 |
US20050131014A1 (en) | 2005-06-16 |
WO2005058834A2 (en) | 2005-06-30 |
PA8619901A1 (es) | 2005-11-25 |
KR20070001922A (ko) | 2007-01-04 |
JP2007516258A (ja) | 2007-06-21 |
WO2005058834A3 (en) | 2005-11-17 |
EP1692111A2 (en) | 2006-08-23 |
RU2006124843A (ru) | 2008-01-20 |
BRPI0417543A (pt) | 2007-03-27 |
TW200529845A (en) | 2005-09-16 |
AU2004298486A1 (en) | 2005-06-30 |
CR8410A (es) | 2006-10-04 |
AR047329A1 (es) | 2006-01-18 |
US7576215B2 (en) | 2009-08-18 |
IL175892A0 (en) | 2006-10-05 |
CA2547518A1 (en) | 2005-06-30 |
PE20050676A1 (es) | 2005-11-02 |
ECSP066635A (es) | 2006-10-25 |
EP2284157A1 (en) | 2011-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2005001973A (es) | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500) | |
ECSP077223A (es) | Indazoles utiles en el tratamiento de enfermedades cardiovasculares | |
ECSP077360A (es) | Compuestos sulfonamida | |
EA200501771A1 (ru) | Лиганды каннабиноидных рецепторов и их применения | |
DK1853602T3 (da) | Kemiske forbindelser | |
DK1853588T3 (da) | Kemiske forbindelser | |
NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
ECSP066355A (es) | Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2 | |
DE602005023172D1 (de) | Hydantoinderivate zur behandlung von entzündlichen erkrankungen | |
ECSP055640A (es) | Composiciones de pirazol útiles como inhibidores de gsk-3 | |
NO20055588D0 (no) | Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2 | |
UA85559C2 (en) | Aminobenzophenone compounds | |
BRPI0509660A (pt) | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias | |
ECSP056006A (es) | Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas | |
ATE443704T1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
ATE410166T1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit | |
ECSP056057A (es) | Compuestos de benzo[1,2,5]tiadiazole | |
UY28248A1 (es) | Compuestos quinicos | |
ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
BRPI0415355A (pt) | triarilimidazóis | |
NO20053562L (no) | Nye aminobenzofenonforbindelser | |
EA200600115A1 (ru) | Производные 2-аминобензойной кислоты | |
DK1687301T3 (da) | Thiaepothilone til behandling af kræftsygdomme | |
ATE433983T1 (de) | Thiadibenzoazulenderivate zur behandlung von entzündlichen erkrankungen | |
IS8496A (is) | Samsetningar til meðhöndlunar á fjölgunarsjúkdómum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Lapse |